Drugs / CPL-01
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05411861 | Jun → Sep 2022 | — | Cali Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 2 | NCT05080959 | Jul → Dec 2021 | hernia, double inguinal | Cali Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07490496 | Jul → Oct 2026 expected | toe, misshapen | Cali Pharmaceuticals LLC | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05831449 | May 2023 → Sep 2025 | toe, misshapen | Cali Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 3 | NCT05813847 | Apr 2023 → Sep 2025 | — | Cali Pharmaceuticals LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPL-01 | “Near the completion of surgery, a single dose of study drug (CPL-01, saline placebo, or ropivacaine HCl) will be infiltrated.” NCT05411861 ↗ |
| Route | Other | “Infiltration of study drug” NCT05080959 ↗ |